Novartis said on Monday it received regulatory clearance to open a separate trading line for potentially up to 16.5 billion Swiss francs ($18.1 billion) in stock repurchases even as its ongoing $15 billion buyback programme is close to completion.
At last week’s annual shareholder meeting, the company won investor authorization for up to 10 billion francs in buybacks, which comes on top of 6.5 billion francs in prior authorizations.
A company spokesperson told Reuters on Monday that the “majority” of its ongoing $15 billion buyback programme was already completed, adding that any repurchases would be decided by the board of directors.
She declined to comment on specific amounts.
Novartis laid out plans for the $15 billion programme in late 2021, after receiving $20.7 billion for the sale of its nearly one-third voting stake in Roche back to its cross-town rival.
The spokesperson said the remainder of that repurchase programme would be carried out while allowing for “bolt-on M&A, whilst providing a strong, growing dividend and reinvesting in the business”.
Novartis’s CEO Vas Narasimhan said in January that the group was looking at the “full range of M&A opportunities”, but the focus was on assets worth no more than $5 billion.
Source : Reuters
The sharp rise in long-term interest rates since 2020 is difficult to explain from slow-moving…
Trade wars do not simply redirect exports; they also reshape the costs of production, disrupt…
Few features of modern work are as widely criticised as meetings. Using data from over…
Forecasts of AI-driven job destruction rest on counting automatable tasks. But labour markets hire, pay,…
US federal government debt exceeded $40 trillion in August 2026, triggering concerns about fiscal credibility…
Global current account imbalances are widening again. This column argues that currency undervaluation, supported by…